Comparative Pharmacology
Head-to-head clinical analysis: METHYLTESTOSTERONE versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLTESTOSTERONE versus ORETON.
METHYLTESTOSTERONE vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category D/X
Category C
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."